Outlook Therapeutics
OTLK
22 hedge funds and large institutions have $3.6M invested in Outlook Therapeutics in 2020 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 6 closing their positions.
316% more capital invested
Capital invested by funds: $865K → $3.6M (+$2.74M)
117% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 6
29% more funds holding
Funds holding: 17 → 22 (+5)
0.35% more ownership
Funds ownership: 0.24% → 0.59% (+0.35%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.36M |
| 2 |
AC
Armistice Capital
New York
|
+$1.17M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$176K |
| 4 |
Bank of New York Mellon
New York
|
+$42.2K |
| 5 |
BRWM
B. Riley Wealth Management
Memphis,
Tennessee
|
+$33.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$23K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$15K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$7K |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
-$6K |
| 5 |
RIA
Realta Investment Advisors
Wilmington,
Delaware
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| – | +$116 | +7 | New |
|
OTLK Hedge Fund Activity: Q1 2020 in Review
22 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q1 2020, worth a combined $3.6M — up 316% from $865K a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new OTLK positions and 6 closed out — a net gain of 7 holders — while 3 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, adding an estimated $2.36M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $23K sold.
- 22 institutional investors held Outlook Therapeutics (OTLK) as of Q1 2020, up from 17 in Q4 2019.
- Funds reported $3.6M of Outlook Therapeutics stock for Q1 2020, up 316% quarter-over-quarter.
- 13 funds opened new Outlook Therapeutics positions in Q1 2020 and 6 closed out, a net change of +7 holders.
- The largest Outlook Therapeutics buyer in Q1 2020 was Sabby Management, an estimated $2.36M added.
- The largest Outlook Therapeutics seller in Q1 2020 was Renaissance Technologies, an estimated $23K sold.
Based on aggregated 13F filings for Q1 2020.